Analystreport

Kalvista Pharmaceuticals Inc (NASDAQ: KALV) is now covered by analysts at Cantor Fitzgerald. They set a "buy" rating and a $32.00 price target on the stock.

KalVista Pharmaceuticals, Inc.  (KALV) 
Last kalvista pharmaceuticals, inc. earnings: 3/10 07:30 am Check Earnings Report
US:NASDAQ Investor Relations: ir.kalvista.com